Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) stock rose 3.02% to $808.05, outperforming competitors like Amgen and Moderna on a generally weak trading day. This marks the fifth consecutive daily gain for Regeneron, leaving it just 1.59% below its 52-week high of $821.11. Trading volume exceeded the 50-day average, indicating strong investor interest despite broader market declines in the S&P 500 and Dow Jones.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) advanced 3.02% to $808.05 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.06% to 7,753.11 and Dow Jones Industrial Average falling 0.11% to 53,975.98.
This was the stock's fifth consecutive day of gains.
Regeneron Pharmaceuticals Inc. closed 1.59% short of its 52-week high of $821.11, which the company achieved on January 9th.
The stock outperformed some of its competitors Monday, as Amgen Inc. (AMGN) rose 1.52% to $417.20, Moderna Inc. (MRNA) rose 1.08% to $59.81, and Gilead Sciences Inc. (GILD) fell 0.11% to $133.06.
Trading volume (991,002) eclipsed its 50-day average volume of 962,464.
Data source: Dow Jones Market Data, FactSet. Data compiled August 10, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-10-26 1644ET